Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268319 · ClinicalTrials.gov registry record · NA
CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow
A NA study, sponsored by Infraredx.
- Terminated
- Registry status
- NA
- Development phase
- 85
- Enrollment target
NCT01268319 is a NA study that was terminated before completion, run by Infraredx. The registered enrollment target is 85 participants.
The verdict
NCT01268319, a NA study, was terminated before completion, sponsored by Infraredx.
- TERMINATED
- Registry status
- NA
- Development phase
- 85 participants
- Enrollment target
Study Summary
The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of care therapy and causing intra-procedural complications. If plaques that require treatment are at higher than normal risk of causing intra-procedural complications, some life threatening, the treating physician is better informed and may opt to take precautionary measures to mitigate the risk or result of a complication. The CANARY Study is also designed to evaluate the feasibility of using a distal embolization protection device (EPD) as a means to prevent heart attacks triggered by the embolization of plaque during standard care therapy. It is thought that the EPD will prevent plaque from going downstream during treatment and obstructing other heart vessels. These obstructions could cause heart attacks by preventing blood from reaching heart muscle tissue.
Interventions
- DEVICE Embolic Protection Device (EPD)
- DEVICE Intracoronary Spectroscopy and Ultrasonic Evaluation
- DEVICE Angioplasty and Stent Implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01268319
The ClinicalTrials.gov registry entry for NCT01268319 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Infraredx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Embolic Protection Device (EPD) is the first listed.
NCT01268319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01268319 about?
NCT01268319 is a clinical study titled "CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow". The CANARY (Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow) Study is a pivotal trial to evaluate criteria for defining a Lipid Core Plaque (LCP) that is at high risk of rupturing during standard of care therapy and causing intra-procedural complications. If plaques that...
What is the current status of trial NCT01268319?
This trial is currently terminated. It is a NA study. The enrollment target is 85 participants. The study started on 2011-05. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01268319?
The interventions under investigation include: Embolic Protection Device (EPD) (DEVICE), Intracoronary Spectroscopy and Ultrasonic Evaluation (DEVICE), Angioplasty and Stent Implant (DEVICE).
Who is sponsoring clinical trial NCT01268319?
This trial is sponsored by Infraredx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.